Clinical trials: Fibromyalgia
Cerebral Palsy, Multiple Sclerosis
The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of…
- Conditions
- Cerebral Palsy, Multiple Sclerosis, Stroke, Neurologic Disorder
- Trial name
- EXOREG (NCT05901259)
- Testing
- EXOPULSE Mollii Suit and EXOPULSE Suit
- Where
- Sweden
- Volunteers
- 200 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Fibromyalgia Syndrome
Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran
Evaluation of the antinociceptive effect of 7 weeks of treatment with milnacipran, compared to placebo, in fibromyalgia out-patients
- Trial name
- NCT00757679
- Testing
- Milnacipran
- Where
- Switzerland
- Volunteers
- 153 people
- Sponsor
- Pierre Fabre Medicament
Fibromyalgia Syndrome
FMS European Long-Term Study
Investigation of the long-term (12 months) efficacy and safety of milnacipran used in the treatment of fibromyalgia syndrome.
- Trial name
- NCT00757731
- Testing
- milnacipran
- Where
- 10 sites in Czechia, Finland and 8 more
- Volunteers
- 490 people
- Sponsor
- Pierre Fabre Medicament
Pain Associated With Fibromyalgia
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
This is an open-label study of DS-5565 in subjects who either completed participation in a preceding Phase 3 study of DS-5565 in fibromyalgia (FM); i.e.
- Trial name
- NCT02234583
- Testing
- DS-5565
- Where
- 276 sites in United States, Australia and 27 more
- Volunteers
- 2,485 people
- Sponsor
- Daiichi Sankyo
Myofascial Pain Syndromes
Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome
The main purpose of this study is to determine which is the best dose of a drug known as Dysport to give when treating one's type of upper back pain.
- Trial name
- NCT00134810
- Testing
- Botulinum toxin type A
- Where
- 22 sites in Czechia, Germany and 4 more
- Volunteers
- 381 people
- Sponsor
- Ipsen
Fibromyalgia
Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301
The purpose of this study is to test the safety and efficacy of a noninvasive cortical electrostimulation therapy known as "Reduced Impedance Noninvasive Cortical Electrostimulation" (RINCE) in the treatment of pain associated…
- Trial name
- PERRFECT-301 (NCT02211508)
- Testing
- RINCE
- Where
- 16 sites in United States
- Volunteers
- 236 people
- Sponsor
- Cerephex Corporation
Chronic Widespread Pain, Fibromyalgia
Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia
This is a randomized, double-blind, placebo-controlled exploratory trial to investigate efficacy and safety of food supplement IGN-ES001 in patients with chronic widespread pain (CWP) with or without fibromyalgia (FM).
- Trial name
- NCT03058224
- Testing
- IGN-ES001, Parol 500 mg Tablets (acetaminophen)
- Where
- 23 sites in Turkey (Türkiye)
- Volunteers
- 230 people
- Sponsor
- IgNova GmbH
Fibromyalgia
Study of Milnacipran for the Treatment of Fibromyalgia
The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.
- Trial name
- NCT00314249
- Testing
- Milnacipran 100mg
- Where
- 24 sites in United States
- Volunteers
- 1,025 people
- Sponsor
- Forest Laboratories
Fibromyalgia
Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia
This was a double-blind, randomised, placebo-controlled, parallel-group, multicentre, multinational, Phase II study in 528 subjects with pain due to Fibromyalgia syndrome(FMS).
- Trial name
- NCT01820585
- Testing
- ESL 400 mg, ESL 800 mg, ESL 1200 mg
- Volunteers
- 528 people
- Sponsor
- Bial - Portela C S.A.
Fibromyalgia
Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
The primary objective is to determine whether daily dosing with NYX-2925 changes markers of central pain processing in subjects with fibromyalgia by evaluating changes in evoked pain, and visual stimulation, functional magnetic…
- Trial name
- NCT03249103
- Testing
- NYX-2925
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aptinyx
Healthy, CVA
Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
DELPhI software developed for the analysis of EEG recordings in response to magnetic stimulation in relation to clinical data.
- Conditions
- Healthy, CVA, Hemorrhage, TBI (Traumatic Brain Injury)
- Trial name
- NCT04095377
- Testing
- No intervention, this is a retrospective study.
- Where
- Israel
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Osteoarthritis, Fibromyalgia
Pilot Study of the Efficacy & Safety of Natural Eggshell Membrane (NEM) for Joint & Connective Tissue Disorders
The purpose of this study was to evaluate the use of the dietary supplement Natural Eggshell Membrane (NEM) for the treatment of joint and connective tissue discomfort, pain, and flexibility.
- Trial name
- NCT00750230
- Testing
- NEM
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- ESM Technologies, LLC
Fibromyalgia, Painful Diabetic Peripheral Neuropathy
Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study
The investigators hypothesize that fibromyalgia (FM) and painful diabetic peripheral neuropathy (pDPN) patients with access restrictions on pregabalin will lead to higher healthcare resource use and cost compared to patients…
- Trial name
- NCT01280747
- Testing
- prior authorization, no prior authorization
- Where
- 17 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fibromyalgia
Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with fibromyalgia syndrome. The study is being conducted in 2 parts.
- Trial name
- NCT00445705
- Testing
- AGN 203818
- Where
- 3 sites in United States, Switzerland and 1 more
- Volunteers
- 211 people
- Sponsor
- Allergan
Fibromyalgia
Adolescent Fibromyalgia Study
This study will compare pregabalin with placebo over a 15 week period in adolescents with fibromyalgia aged 12-17 years to evaluate the safety and efficacy of pregabalin.
- Trial name
- NCT01020474
- Testing
- pregabalin (Lyrica)
- Where
- 36 sites in United States, Czechia and 2 more
- Volunteers
- 107 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Myofascial Pain Syndromes
Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
The main purpose of this study is to determine the effectiveness and safety of one dose of botulinum toxin type A (Dysport) associated with rehabilitation treatment on pain control in patients with a type of back pain called…
- Trial name
- NCT00149240
- Testing
- Botulinum toxin type A
- Where
- 4 sites in Spain
- Volunteers
- 24 people
- Sponsor
- Ipsen
Fibromyalgia
An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)
The purpose of the study is to assess the safety and efficacy of duloxetine in participants with fibromyalgia at long-term use.
- Trial name
- NCT01621191
- Testing
- Duloxetine
- Where
- Japan
- Volunteers
- 149 people
- Sponsor
- Eli Lilly and Company